April 2023 in “Journal of Investigative Dermatology” In this retrospective cohort study, 53.8% of adult rosacea patients who started CGRP monoclonal antibodies for migraines experienced improvement in papules/pustules and erythema/flushing, although moderate adverse events were noted, suggesting these antibodies may benefit rosacea symptoms.
January 2024 in “Wiadomości Lekarskie” In this study, researchers developed a novel computational framework using deep reinforcement learning to identify strategies for cellular reprogramming in gene regulatory networks, showing its effectiveness in a model of immune response against infection.
7 citations
,
September 2017 in “Pharmacoepidemiology and Drug Safety” This study observed a strong overall reduction in the use of CPA/EE in the Netherlands, despite similar proportions of users with acne or other hyperandrogenic conditions before and after the referral procedure.
January 2019 in “Industrial Law Journal” This article reviews two new legislative measures affecting domiciliary care workers in Wales and reports no new research results; it highlights implications for labor law and devolution debates.
14 citations
,
September 2019 in “Eye” This review discusses the evidence for using oral medications to treat central serous chorioretinopathy, highlighting eplerenone as having the most support despite a lack of robust efficacy across studies.
In this study, researchers analyzed over 5,000 T cells per sample using scRNA+TCR-seq technology and found that dual TCR Tregs are present in high proportions across various mouse tissues, showing unique TCR pairing patterns, V(D)J usage, and mRNA expression compared to single TCR Tregs.
70 citations
,
December 2008 in “Cancer Research” This study found that activating CXCR2 on ras-transformed keratinocytes promotes migration and tumor development in a mouse skin model.
September 2024 in “Drugs & Therapy Perspectives” In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.
3 citations
,
April 2017 in “Clinical Drug Investigation” The researchers concluded that after the 2013 EMA recommendation, there was an overall reduction in CPA/EE prescriptions, but no substantial change in patient diagnoses or potential concurrent hormonal contraceptive use.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This research outlines an innovative bioregeneration chamber aimed at significantly extending human lifespan and enhancing health maintenance by treating the body as a thermodynamic system, potentially enabling an average lifespan of 130 to 150 years in an advanced therapeutic setting.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, researchers found that CCCA in women of African descent is associated with molecular changes, including dysregulation of fatty acid metabolism and fibrosis pathways, suggesting potential targets for new treatments.
23 citations
,
June 1992 in “PubMed” This study found that RAR-gamma 1 mRNA is present in multiple skin layers and structures, suggesting a role in maintaining and differentiating normal epidermis and skin appendages.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.
6 citations
,
October 2016 in “Contraception” This study found that most UK women prescribed cyproterone acetate/ethinylestradiol before and after 2013 had conditions aligning with approved indications and prior acne treatment.
13 citations
,
February 2019 in “Türk oftalmoloji dergisi” This review discusses various treatment options for chronic central serous chorioretinopathy, evaluating studies conducted since 2000, but reports no new clinical results.
9 citations
,
August 2021 in “Biomedicines” This study found that 17β-estradiol was the most powerful hormone for inducing APE1/Ref-1 secretion in cultured vascular endothelial cells, with secretion occurring through exosomes dependent on estrogen receptors and intracellular calcium.
1 citations
,
November 2022 in “Indian Journal of Dermatology/Indian journal of dermatology” This case study describes a 12-year-old boy with an unruptured epidermal inclusion cyst on his cheek, highlighting the role of dermatoscopy in diagnosing and differentiating cyst types for treatment.
November 2025 in “SKIN The Journal of Cutaneous Medicine” This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.
January 2025 in “Turkish Journal of Cerebrovascular Diseases” This case report details two consanguineous patients with cerebral autosomal recessive arteriopathy, both having the same HTRA1 gene mutation, but exhibiting different clinical presentations, including one with epileptic seizures and lobar hemorrhages—previously undocumented in this condition.
5 citations
,
December 2023 in “Current Biology” A feedback loop between LRH and RSL4 controls root hair growth in Arabidopsis.
December 2025 in “Actas Dermo-Sifiliográficas” This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.
119 citations
,
October 2011 in “Journal of Veterinary Internal Medicine” This review discusses the clinical manifestations and immune response to Rhodococcus equi infection in foals but reports no new clinical results.
March 2026 in “The Journal of Dermatology” This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.
November 2023 in “Research Square (Research Square)” In this study, researchers used NIR-II fluorescence imaging to track the survival and migration of EPI-NCSCs in rat models, finding that these stem cells aided in repairing facial nerve defects when applied via acellular nerve allografts.
March 2023 in “Pediatrics & neonatology” This case study reported a successful surgical excision of two cephalocele lesions in a female neonate, resulting in uneventful recovery and appropriate neurodevelopment during a seven-month follow-up.
This study investigated dual TCR Treg cells in mouse tissues, revealing a high proportion and diverse pairing patterns compared to single TCR Tregs, providing insights into their origins and characteristics across different tissue locations.
April 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that CTCF is crucial for proper skin and hair follicle development in mice, affecting keratinocyte differentiation and gene expression in keratin loci.
9 citations
,
January 2013 in “Case reports in emergency medicine” This case study reports that Citrullus colocynthis can cause severe gastrointestinal symptoms, including rectorrhagia and mucosal erosion, highlighting the need for awareness of its potential side effects.
February 2026 in “Trials” The Exfoliate-Dissolve-Repair skincare approach may effectively treat keratosis pilaris and reduce the need for corticosteroids.